FDA approves Merck’s lung cancer drug as first-line treatment

Your Health Matters

(Reuters) – Merck & Co Inc on Monday said the U.S. Food and Drug Administration has approved its immunotherapy Keytruda for use in certain previously untreated lung cancer patients, making it the only approved first-line treatment. The drug has been approved for treating metastatic non-small cell lung cancer (NSCLC) patients with high-levels of a protein known for suppressing the immune system called PD-L1. The drug has already been approved for patients who have undergone previous chemotherapy for advanced non-small lung cancer.
Go to Source

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave